Phaseline

Companies › Syntara

Syntara: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PXS-4728A
LRRK2 inhibitor
LRRK2Phase 2REM Sleep Behavior Disorder–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05904717PXS-4728APhase 2REM Sleep Behavior DisorderNeurologySep 2024

Targets

LRRK2 (1)

Companies with the same targets

Neuron23 Denali Therapeutics Eli Lilly

Companies built like this

Neuron23 Aptinyx Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.